Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.

Repaglinide and nateglinide represent a new class of insulin secretagogues, structurally unrelated to sulphonylureas, that were developed for the treatment of type 2 diabetes. The inhibitory effect of these drugs was investigated on recombinant wild-type and mutant Kir6.2/SUR1 channels expressed in...

詳細記述

書誌詳細
主要な著者: Hansen, A, Christensen, I, Hansen, J, Carr, R, Ashcroft, F, Wahl, P
フォーマット: Journal article
言語:English
出版事項: 2002